請用此 Handle URI 來引用此文件：
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/31632完整後設資料紀錄
| DC 欄位 | 值 | 語言 |
|---|---|---|
| dc.contributor.advisor | 季昭華 | |
| dc.contributor.author | Chien-Liang Lin | en |
| dc.contributor.author | 林建良 | zh_TW |
| dc.date.accessioned | 2021-06-13T03:16:16Z | - |
| dc.date.available | 2006-07-31 | |
| dc.date.copyright | 2006-07-31 | |
| dc.date.issued | 2006 | |
| dc.date.submitted | 2006-07-31 | |
| dc.identifier.citation | 1. Michael HC, Allan SJ, Wayne LM. Diagnosis & Treatment in Cardiology, 2th. New York: McGraw-Hill. 2003;5:57-87.
2. Nappi JM. Myocardial Infarction. In: Koda-kimble M, Young L, eds. Applied Therapeutics-The Clinical Use Drugs, 7th. Baltimore: Lippincott Willams & Wilkins. 2001;16:1-24. 3. http://www.ch.com.tw/。啟新健康世界，2003。 4. Kathleen A, Larry M. Myocardial Infarction. In: Joseph T, Robert L, Gary C, eds. Pharmacotherapy A Pathophysiologic Apporach, 4th ed. Stanford: Appleton & Lange, 1999:211-231. 5. 賴世珍、周美惠、林明芳。心肌梗塞之藥物治療新趨勢。臨床醫學，2002;49:99-105。 6. http://www.doh.gov.tw/cht/content.aspx?doc_no=45219，國人主要死因統計。行政院衛生署，2006。 7. Bruce FW, Robert CS. Anatomy of the Heart, 9th ed. New York: McGraw-Hill, 1998;2:19-81. 8. Rang HP, Ritter JM, Dale MM, Gardner P. Pharmacology, 3th ed. Philadelphia: Churchill Livings stone, 1998;13:244-272. 9. Stephen MF, Robert JB. Pathophysiology of Myocardial Ischemia. 9th ed. New York: McGraw-Hill,1998;43:1241-1262. 10. Canto JG, Shlipak MG, Rogers WJ, et al. Prevalence, clinical characteristics, and mortality among patients with myocardial infarction presenting without chest pain. JAMA. 2000;283:3223-3229. 11. Schoen FJ. The Heart. In : Cotran RS, et al., eds. Robbins Pathologic Basis of Disease, 6th ed. Philadelphia: W.B. Saunders, 1999;13:546-564. 12. Davies MJ. The pathophysiology of acute coronary syndromes. Heart 2000;83:361-366. 13. Maynard SJ, Scott GO, Riddell Jw, Adgey AA. Management of acute coronary syndromes. BMJ 2000;321:220-223. 14. McGovern PG, Pankow JS, Shahar E, et al. Recent trends in acute coronary heart disease: Mortality, morbidity, medical care, and risk factors. N Engl J Med 1996; 334:884-890. 15. Robert CS, Alexander RW. Hurst’s The Heart. 8th ed. New York: McGraw-Hill, 1995;10:113-131. 16. Cinitron GB, Hernandez E, Livares E, et al. Bedside recognition, incidence and clinical course of right ventricular infarction. Am J Cardiol 1981;47:224-227. 17. Marc SS. Pocket Medicine 1st ed. Philladophia. Lippincott Willams & Wilkins, 2000;1:10-13. 18. Ross R. The pathogenesis of atherosclerosis-A perspective for the 1990s. Nature 1993;362:801-809. 19. Choudhury L, Marsh JD. Myocardial infarction in young patients. Am J Med 1999;107:254-261. 20. Fuster V, Pearson TA. 27th Bethesda Conference: Matching the intensity of risk factor management with the hazard for coronary heart disease events. J Am Coll Cardiol 1996;27:957-1047. 21. Frei B, Forte TM, Ames BN, Cross CE. Gas phase oxidants of cigarette smoke induce lipid peroxidation and changes in lipoprotein properties in human blood plasma. Protective effects of ascorbic acid. Biochem J 1991;277:133-138. 22. Celermajer DS, Sorensen KE, Georgakopoulos D, et al. Cigarette smoking is associated with dose-related and potentially reversible improvement of endothelium-dependent dilation in healthy young adults. Circulation 1993;88:2149-2155. 23. Folsom AR, Wu KK, Davis CE, Conlan MG, Sorlie PD, Szklo M. Population correlates of plasma fibrinogen and factor Ⅶ, protective cardiovascular risk factors. Atherosclerosis 1991;91:191-205. 24. Goldman L, Garber AM, Grover SA, Hlatky MA. Cost- effectiveness of assessment and management of risk factors. J Am Coll Cardiol 1996;27:1020-1030. 25. Alexander RW, Robert R, Craig MP. Diagnosis and Management of Patients with Acute Myocardial Infarction. 9th ed. New York: McGraw-Hill,1998:46,47:1307-1434. 26. Dewood MA, Sporess J, Notske R et al. Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction. N Engl J Med 1980;303:897. 27. Anderson HV, Willerson JT. Current concepts:thrombolysis in acute myocardial infarction. N Engl J Med 1993;329:703-709. 28. David MK, Rose MR, David R. Drugs used for the treatment of myocardial ischemia. 10th ed. New York: McGraw-Hill, 2001; 32:843-865. 29. Bauer JA, Fung HL. Arterial versus venous metabolism of nitroglycerin to nitric oxide: a possible explanation of organic nitrate venoselectivity. J Cardiovasc. Pharmacol 1996;28:371-374. 30. Cyrus T, Witztum JL, Rader DJ,et al. Disruption of the 12/15-lipoxygenase gene diminishes atherosclerosis in apo E-deficient mice. J Clin Invest 1999;103:1597-1604. 31. Deedwania PC, Carbajal EV. Role of beta blockade in the treatment of myocardial ischemia. Am J Cardiol 1997;80:23J-28J. 32. Kloner RA. Nifedipine in ischemic heart diaease. Circulation 1995;92:1074-1078. 33. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-coverting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342:145-153. 34. Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K.Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature. 1999;402:656-660. 35. Howard AD, Feighner SD, Cully DF, et al. A receptor in pituitary and hypothalamus that functions in growth hormone release. Science. 1996;273:974-977. 36. Gnanapavan S, Kola B, Bustin SA, Morris DG, McGee P, Fairclough P,et al. The tissue distribution of the mRNA of ghrelin and subtypes of its receptor, GHS-R, in humans. J Clin Endocrinol Metab. 2002;87: 2988-2991. 37. Korbonits M, Bustin SA, Kojima M, Jordan S, Adams EF, Lowe DG, Kangawa K, Grossman AB. The expression of the growth hormone secretagogue receptor ligand ghrelin in normal and abnormal human pituitary and other neuroendocrine tumors. J Clin Endocrinol Metab. 2001;86:881-887. 38. DelParigi A, Tschop M, Heiman ML, Salbe AD, Vozarova B, Sell SM, Bunt JC, Tataranni PA. High circulating ghrelin: a potential cause for hyperphagia and obesity in prader-willi syndrome. J Clin Endocrinol Metab. 2002;87:5461-5464. 39. Meier U, Gressner A: Endocrine Regulation of Energy Metabolism: Review of Pathobiochemical and Clinical Chemical Aspects of Leptin, Ghrelin, Adiponectin, and Resistin. Clin Chem. 2004;50:1511-1525. 40. Nagaya N, Kojima M, Uematsu M, Yamagishi M, Hosoda H, Oya H, Hayashi Y, Kangawa K. Hemodynamic and hormonal effects of human ghrelin in healthy volunteers. Am J Physiol Regul Integr Comp Physiol. 2001;280:1483-1487. 41. Caminos JE, Tena-Sempere M, Gaytan F, et al. Expression of ghrelin in the cyclic and pregnant rat ovary. Endocrinology 2003;144: 1594–602. 42. Cassoni P, Papotti M, Ghe C, Catapano F, Sapino A, Graziani A, Deghenghi R, Reissmann T, Ghigo E, Muccioli G. Identification, characterization, and biological activity of specific receptors for natural (ghrelin) and synthetic growth hormone secretagogues and analogs in human breast carcinomas and cell lines. J Clin Endocrinol Metab. 2001; 86: 1738-1745. 43. Bedendi I, Alloatti G, Marcantoni A, Malan D, Catapano F, Ghe C, Deghenghi R, Ghigo E, Muccioli G. Cardiac effects of ghrelin and its endogenous derivatives des-octanoyl ghrelin and des-Gln14- ghrelin. EurJ Pharmacol. 2003;476:87-95. 44. Hosoda H, Kojima M, Matsuo H, Kangawa K. Ghrelin and des-acyl ghrelin: two major forms of rat ghrelin peptide in gastrointestinal tissue. Biochem Biophys Res Commun. 2000;279:909-913. 45. Muccioli G, Tschop M, Papotti M, Deghenghi R, Heiman M, Ghigo E. Neuroendocrine and peripheral activities of ghrelin: implications in metabolism and obesity. Eur J Pharmacol. 2002;440:235-254. 46. Torsello A, Ghe' C, Bresciani E, Catapano F, Ghigo E, Deghenghi R, Locatelli V, Muccioli G. Short ghrelin peptides neither displace ghrelin binding in vitro nor stimulate GH release in vivo. Endocrinology. 2002;143:1968-1971. 47. Gualillo O, Lago F, Go´mez-Reino J, Casanueva FF, Die´guez C. Ghrelin, a widespread hormone:insights into molecular and cellular regulation of its expression and mechanism of action. FEBS Lett 2003; 552:105– 9. 48. Korbonits M, Goldstone AP, Gueorguiev M, Grossman AB. Ghrelin--a hormone with multiple functions. Front Neuroendocrinol. 2004 Apr;25(1):27-68. 49. Kenchaiah S, Evans JC, Levy D, et al. Obesity and the risk of heart failure. N Engl J Med 2002;347:305– 13. 50. Colao A, Marzullo P, Di Somma C. Growth hormone and the heart. Clin Endocrinol (Oxf) 2001;54:137– 54. 51. Tivesten A, Bollano E, Caidahl K, Kujacic V, Sun XY, Hedner T, Hjalmarson A, Bengtsson BA, Isgaard J. The growth hormone secretagogue hexarelin improves cardiac function in rats after experimental myocardial infarction. Endocrinology. 2000; 141: 60-66. 52. Iglesias MJ, Pineiro R, Blanco M, Gallego R, Dieguez C, Gualillo O, Gonzalez-Juanatey JR, Lago F. Growth hormone releasing peptide (ghrelin) is synthesized and secreted by cardiomyocytes. Cardiovasc Res. 2004 Jun 1;62(3):481-8. 53. Tscho¨p M, Weyer C, Tataranni PA, Devanarayan V, Ravussin E, Heiman ML. Circulating ghrelin levels are decreased in human obesity. Diabetes 2001;50:707–9. 54. Shiiya T, Nakazato M, Mizuta M, et al. Plasma ghrelin levels in lean and obese humans and the effect of glucose on ghrelin secretion. J Clin Endocrinol Metab 2002;87:240–4. 55. Kang PM, Izumo S. Apoptosis and heart failure: a critical review of the literature. Circ Res 2000;86:1107– 13. 56. Schunkert H. Obesity and target organ damage: the heart. Int J Obes Relat Metab Disord 2002;26:S15– 20. 57. Wiley KE, Davenport AP. Comparison of vasodilators in human internal mammary artery: ghrelin is a potent physiological antagonist of endothelin-1. Br J Pharmacol 2002;136:1146– 52. 58. Bisi G, Podio V, Valetto MR, Broglio F, Bertuccio G, Aimaretti G, Pelosi E, Del Rio G, Muccioli G, Ong H, Boghen MF, Deghenghi R, Ghigo E. Cardiac effects of hexarelin in hypopituitary adults. Eur J Pharmacol. 1999;381:31-38. 59. Wren A.M, Seal LJ, Cohen MA, et al. Ghrelin enhances appetite and increases food intake in humans. J Clin Endocrinol Metab 2001; 86:5992. 60. Okumura H, Nagaya N, Enomoto M, Nakagawa E, Oya H, Kangawa K. Vasodilatory effect of ghrelin, an endogenous peptide from the stomach. J Cardiovasc Pharmacol 2002;39:779– 83. 61. Nagaya N, Miyatake K, Uematsu M, Oya H, Shimizu W, Hosoda H, Kojima M, Nakanishi N, Mori H, Kangawa K. Hemodynamic, renal, and hormonal effects of ghrelin infusion in patients with chronic heart failure. J Clin Endocrinol Metab. 2001;86:5854-5859. 62. King MK, Gay DM, Pan LC, McElmurray JH 3rd, Hendrick JW, Pirie C, Morrison A, Ding C, Mukherjee R, Spinale FG. Treatment with a growth hormone secretagogue in a model of developing heart failure: effects on ventricular and myocyte function. Circulation. 2001;103:308-313. 63. Locatelli V, Rossoni G, Schweiger F, Torsello A, De Gennaro Colonna V, Bernareggi M, Deghenghi R, Muller EE, Berti F. Growth hormone-independent cardioprotective effects of hexarelin in the rat. Endocrinology. 1999;140:4024-4031. 64. Chang L, Zhao J, Li GZ, Geng B, Pan CS, Qi YF, Tang CS. Ghrelin protects myocardium from isoproterenol-induced injury in rats. Acta Pharmacol Sin. 2004;25:1131-1137. 65. Lawrence CB, Snape AC, Baudoin F, Luckman SM. Acute central ghrelin and GH secretagogues induce feeding and activate brain appetite centers. Endocrinology 2002;143:155– 62. 66. Seoane LM, Lo´pez M, Tovar S, Casanueva FF, Senaris R, Dieguez C. Agouti-related peptide, neuropeptide Y, and somatostatin-producing neurons are targets for ghrelin actions in the rat hypothalamus. Endocrinology 2003;144:544– 51. 67. Tena-Sempere M, Barreiro ML, Gonza´lez LC, et al. Novel expression and functional role of ghrelin in rat testis. Endocrinology 2002;143: 717– 25. 68. Kvist-Reimer M, Pacini G, Ahren B. Dose-dependent inhibition by ghrelin of insulin secretion in the mouse. Endocrinology 2003;144: 916–21. 69. Tscho¨p M, Smiley DL, Heiman ML. Ghrelin induces adiposity in rodents. Nature 2000;407:908–13. 70. Nakazato M, Murakami N, Date Y, et al. A role for ghrelin in the central regulation of feeding. Nature 2001;409:194– 8. 71. Nagaya N, Uematsu M, Kojima M, et al. Chronic administration of ghrelin improves left ventricular dysfunction and attenuates development of cardiac cachexia in rats with heart failure. Circulation 2001; 104:1430– 5. 72. Nagaya N, Uematsu M, Kojima M, et al. Elevated circulating level of ghrelin in cachexia associated with chronic heart failure. Circulation 2001;104:2034– 8. 73. Chang L, Du JB, Gao LR, Pang YZ, Tang CS. Effect of ghrelin on septic shock in rats. Acta Pharmacol Sin 2003;24:45 –9. 74. Matsumura K, Tsuchihashi T, Fujii K, Abe I, Iida M. Central ghrelin modulates sympathetic activity in conscious rabbits. Hypertension 2002;40:694– 9. 75. Pettersson I, Muccioli G, Granata R, et al. Natural (ghrelin) and synthetic (hexarelin) GH secretagogues stimulate H9c2 cardiomyocyte cell proliferation. J Endocrinol 2002;175:201– 9. 76. Baldanzi G, Filigheddu N, Cutrupi S, et al. Ghrelin and des-acyl ghrelin inhibit cell death in cardiomyocytes and endothelial cells through ERK1/2 and PI3-kinase/AKT. J Cell Biol 2002;159:1029 –37. 77. Cassoni P, Papotti M, Ghe´ C, et al. Identification, characterization, and biological activity of specific receptors for natural (ghrelin) and synthetic growth hormone secretagogues and analogs in human breast carcinomas and cell lines. J Clin Endocrinol Metab 2001;86: 1738– 45. 78. Ghe´ C, Cassoni P, Catapano F, et al. The antiproliferative effect of synthetic peptidyl GH secretagogues in human CALU-1 lung carcinoma cells. Endocrinology 2002;143:484– 91. 79. Volante M, Allia E, Fulcheri E, et al. Ghrelin in fetal thyroid and follicular tumors and cell lines: expression and effects on tumor growth. Am J Pathol 2003;162:645– 54. 80. Murata M, Okimura Y, Iida K, et al. Ghrelin modulates the downstream molecules of insulin signaling in hepatoma cells. J Biol Chem 2002;277:5667 –74. 81. Jeffery PL, Herington AC, Chopin LK. Expression and action of the growth hormone releasing peptide ghrelin and its receptor in prostate cancer cell lines. J Endocrinol 2002;172:R7– 11. 82. Andreis PG, Malendowicz LK, Trejter M, et al. Ghrelin and growth hormone secretagogue receptor are expressed in the rat adrenal cortex: evidence that ghrelin stimulates the growth but not the secretory activity of adrenal cells. FEBS Lett 2003;536:173–9. 83. Konits M, Grossman AB. Ghrelin: update on a novel hormonal system.Eur J Endocrinol. 2004 Aug;151 Suppl 1:S67-70. Review. 84. Popovic V, Leal A, Micic D, Koppeschaar HPF, Torres E, Paramo C, Obradovic S, Dieguez C & Casanueva FF. GH-releasing hormone and GH-releasing peptide-6 for diagnostic testing in GH-deficient adults. Lancet 2000; 356: 1137–1142. 85. 常用藥物治療手冊.陳長安.全國藥品年鑑雜誌社.台北.2003. p481-482 86. 得安穩膠囊說明書.台灣諾華股份有限公司.台北.2006 87. http://www.diovan.info/chinese/chinese/diovan01.shtm1 88. 常用藥物治療手冊.陳長安.全國藥品年鑑雜誌社.台北.2003. p489-490 89. 捷賜瑞錠說明書.台灣捷利康股份有限公司.台北.2006 90. http://www.vhcy.gov.tw/PHA/drug/web/Lisinopril%20zestril.htm | |
| dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/31632 | - |
| dc.description.abstract | 心臟冠狀動脈栓塞所引起的急性心肌梗塞，是世界各國常見的十大死因之一，而1999年Kojima等人從大鼠胃臟內分泌細胞中新發現的一種蛋白質『Ghrelin』則被研究證明具有保護心臟的功能。它是由28個胺基酸所組成的醯基化多胜，主要在胃臟、腦垂腺與下視丘存在，而在其他多種組織內也有少量發現。它引人注目的主要原因是與身體能量調節以及體重恆定有關，可以刺激生長激素釋放，增加食慾與肥胖發生。
此外，Ghrelin也具有其他多種作用，包括：抑制心肌細胞因AraC造成的細胞凋零；在健康的志願者中發現，在不會增加心跳速率的情況下可以減少心臟afterload與增加心輸出量；減少血管擴張；改善慢性心臟衰竭病人（CHF）的血液動力學；調節敗血性休克大鼠的心臟血管作用。 根據前人研究顯示，Ghrelin對心臟血管是有益的。然而，Ghrelin在心肌梗塞所扮演的調節角色卻少有人知，因此本論文的目的在探討心肌梗塞的模式中Ghrelin所扮演的調節角色。在本實驗中，利用Wistar雄性大白鼠在2.5月齡時，在其心臟冠狀動脈的左前下降支以手術方式結紮，引發其急性心肌梗塞，之後再依時間點取下心肌組織，做Ghrelin基因變化情形的分析。藉此瞭解此動物模式是否能提供作為ghrelin基因的研究，進而評估此基因的變化及其與心臟功能降低間的關係。 本研究證明Ghrelin會隨著心肌梗塞時間延長而在心肌缺血一天後至四週的左心室組織當中會增加表現，在五天時達到最高表現量。免疫組織染色加上血液動力學與超音波學之檢測可以確認北方墨點與西方墨點轉印法的結果，表示ghrelin可以持續表現，即使是在急性心肌梗塞的情況下。 使用ghrelin的基因治療將會被研究對於心肌梗塞是否成為有效的治療方式。本篇研究或許可以提供一項基礎資料，作為未來發展對於急性心肌梗塞，能夠提供更具療效的治療方式。 | zh_TW |
| dc.description.abstract | The acute myocardial infarction caused by coronary artery embolism is one of the common diseases around the world. A protein called ‘ghrelin’ was first isolated from rat stomach endocrine cells by kojima et al.in 1999 and its function of cardiac protection been proved found.It is a 28-amino-acid acylated peptide. It is found mainly in the stomach, pituitary and hypothalamus, but also found in numerous other tissues at lower levels. It could stimulate the release of growth hormone (GH) and also promote appetite and adiposity. In addition to other effects, it is involved in the regulation of energy balance and body weight homeostasis.
In addition, ghrelin also has many effects, such as inhibiting cardiomyocyte AraC-induced apoptosis, reducing cardiac afterload and increasing cardiac output without increasing heart rate in healthy volunteers, inducing vasodilation, improving the haemodynamics of patients with chronic heart failure (CHF), and regulating cardiovascular function in rats suffering septic shock. According to previous studies, the fact that ghrelin has beneficial cardiovascular effects was confirmed. However, little is known about the regulation of ghrelin in response to myocardial infarction. The purpose of this study was to investigate the role of the ghrelin in myocardial infarction. In this experiment, acute myocardial infarction ( AMI ) is going to be produced in 2.5 month-old male Wistar rats by ligating proximal left anterior descending ( LAD ) coronary artery with 6-0 silk suture. Rat cardiac ventricular tissues will be collected for analyszing the change of ghrelin gene to realize whether such a murine model can be a used as a model of AMI for ghrelin and evaluate the relationship between the chage of ghrelin and decline of cardiac function ? After ligation of the left anterior descending coronary artery, expression of ghrelin significantly increased from 1 day to 4 weeks at left ventricle, and reached maximum at 5 days. Findings of Immuno- histochemical stain、hemodynamics and echocardiography can be confirmed the findings from Northern and Western blots. So it suggested that ghrelin could consist express even in AMI situation. Gene therapy with ghrelin gene will be studied to see whether such a treatment is effective for myocardial infarction. This study may provide a fundamental basis for the development of more effective therapies in AMI treatment. | en |
| dc.description.provenance | Made available in DSpace on 2021-06-13T03:16:16Z (GMT). No. of bitstreams: 1 ntu-95-R91629028-1.pdf: 2216465 bytes, checksum: 656b250e0db6c980da491c76ca3fd62c (MD5) Previous issue date: 2006 | en |
| dc.description.tableofcontents | 目次……………………………………………………………………..Ⅰ
節次……………………………………………………………………..Ⅳ 表次……………………………………………………………………..Ⅵ 中文摘要…………………………………………………...…………….1 英文摘要……………………………………………………………...….3 壹、研究背景.…………..………………..……………………….……..5 第一章 心肌梗塞………………………………………………………..5 第一節 緒言………...….………..……………..……………………..5 第二節 心臟需氧解剖生理………………….……..….………....…..6 第三節 心肌缺血之病理…….……..…………….…………….…….7 第四節 冠狀動脈血栓的形成因子…………………………………..7 1.4.1 動脈血管內膜損傷……………….…………….…..……..7 1.4.2 血栓系統的活化……………………………..…….……...8 1.4.3 冠狀動脈痙攣………..………………………….………...8 1.4.4 其他因子……………..…………………………...……….9 第五節 左冠狀動脈前下降支與心肌梗塞………...……….………..9 第六節 造成心肌梗塞危險因子………...……………….…………10 第七節 心肌梗塞發作症狀…….…………..……………….….…...12 第八節 目前急性心肌梗塞常用的治療方式.……..….……….…...14 1.8.1 藥物治療與藥理機轉.………….………......……………14 1.8.2 外科手術處理….…………………………….….…..…...16 第九節 心肌梗塞後常見的併發症.……….……………..…….…...17 第二章 Ghrelin基因…………………………………………………...18 第一節 來源………………………………………………...…….....18 第二節 結構與序列………….…………………………….………..19 第三節 功能與作用………………………………………….……...19 第三章 藥物介紹………………………………………………………22 第一節 安德穩膠囊……………………………..………………..…23 第二節 捷賜瑞錠………………………………..…………….…….25 貳、研究動機………………………………………..…………………..28 參、研究方法與步驟……………………………………………………29 第一節 實驗動物與實驗分組.……………………………..……….29 第二節 手術處理………..…………………………………….…….30 第三節 左心室功能測量…………………………………....………32 第四節 檢體收集….……………………………………..………….33 第五節 心臟組織Total RNA的萃取……….…………...………….33 第六節 RNA分析…………………………………………………...34 3.6.1 cDNA 探針的製備…………………………...…..…...…34 3.6.2 Northern Blot………………………………………..…….36 第七節 Total protein的抽取………..…………………………..…...37 第八節 Protein 分析（Western Blot）..…………………….………38 第九節 免疫組織化學染色..……..……...………………………….40 第十節 統計分析…...………………………..……...………………41 肆、結果………………………………………………………………..43 第一節 手術結紮確認………..………………………………..……43 第二節 手術存活率………….………………………………….…..44 第三節 手術前後體重變化……….…………………………….…..44 第四節 左心室功能測定……………………………………………45 4.4.1 心跳（Heart rate, HR）………………………………….45 4.4.2 左心室收縮壓（Left ventricular systolic pressure, LVSP）.…………………………………………………45 4.4.3 都卜勒超音波……………………………………………46 第五節 心室組織mRNA表現測定……………………..………….50 第六節 心室組織蛋白質表現測定…………………………………50 第七節 免疫組織化學染色…………..……………………………..51 伍、討論……………………………….………………...……………..53 陸、參考文獻……………………………………............……………..64 | |
| dc.language.iso | zh-TW | |
| dc.title | 在大白鼠急性心肌梗塞模式下探討Ghrelin基因表現之調控 | zh_TW |
| dc.title | Regulation of Gene Expression of Ghrelinin in a Rat Model of Myocardial Infarction | en |
| dc.type | Thesis | |
| dc.date.schoolyear | 94-2 | |
| dc.description.degree | 碩士 | |
| dc.contributor.coadvisor | 徐國基 | |
| dc.contributor.oralexamcommittee | 吳應寧,林中天 | |
| dc.subject.keyword | 冠狀動脈栓塞,急性心肌梗塞,Ghrelin,心臟血管,免疫組織染色,西方墨點轉印法,北方墨點轉印法, | zh_TW |
| dc.subject.keyword | coronary artery embolism,acute myocardial infarction,ghrelin,cardiovascular system,Immunohistochemical stain,Northern blots,Western blots, | en |
| dc.relation.page | 105 | |
| dc.rights.note | 有償授權 | |
| dc.date.accepted | 2006-07-31 | |
| dc.contributor.author-college | 生物資源暨農學院 | zh_TW |
| dc.contributor.author-dept | 獸醫學研究所 | zh_TW |
| 顯示於系所單位： | 獸醫學系 | |
文件中的檔案：
| 檔案 | 大小 | 格式 | |
|---|---|---|---|
| ntu-95-1.pdf 目前未授權公開取用 | 2.16 MB | Adobe PDF |
系統中的文件，除了特別指名其著作權條款之外，均受到著作權保護，並且保留所有的權利。